Monday, June 15, 2020

SUN PHARMA inks EXCL licensing & dist pact for medicine to treat psoriasis


VADODARA (BARODA) / MUMBAI / RAJKOT - In a regulatory update as submitted to the Indian Stock Exchanges, Vadodara (Baroda) headquartered pharmaceutical products manufacturing Indian company Sun Pharmaceutical Industries Ltd said of one of its subsidiaries having inked and entered into an exclusive agreement with London (UK) based Hikma Pharmaceuticals PLC for an exclusive licensing and distribution for Middle East & North African (MENA) regions, for a medicine used to treat psoriasis.

In a press-release titled, "Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA™ for Middle East & North Africa regions", as attached and enclosed with the regulatory filing as submitted by the company to the Indian Bourses, which further read that, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) announced that one of its wholly-owned subsidiaries and Hikma Pharmaceuticals PLC (Hikma) have entered into an exclusive licensing and distribution agreement for ILUMYA™, an innovative biologic product, for the Middle East & North Africa (MENA) region.


ILUMYA™ (tildrakizumab) is an USFDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialization of the product in all MENA markets and Sun Pharma will be responsible for product supply.

Sun Pharma is eligible for upfront and milestone payments from Hikma.

The term of this agreement is 15 years from first sale, with two years’ automatic renewal periods.


In case, if you wish to VERIFY, the above narrated news-report, please CLICK here.

You can also access and/or read the above narrated news-report on our WEBSITE.

No comments:

Post a Comment